PODCAST: Significant catalysts on the horizon

In the latest edition of our regular podcast that looks at upcoming catalysts, I was delighted to welcome Jacob Plieth into the studio for a chat. 

Jacob, Evaluate Vantage’s oncology expert, talks through the once-lauded Tigit mechanism and considers whether its time has finally come. We also discuss the next wave of antibody drug conjugates beyond Enhertu and take a quick look at subcutaneous immunotherapies, such as Keytruda, as companies try to extend the shelf life of these big selling drugs. 

Lastly, I’ll discuss the projects trying to compete in Nash after Madrigal’s recent success, and the drugs gaining ground in a busy IgA nephropathy pipeline. 

It’s all in a nice 10 minute package, so grab your headphones and take a listen. You’ll also find all the stories we reference, alongside some recent key readouts, conveniently placed below. Enjoy!
 

Our upcoming catalyst stories

• Immuno-oncology goes subcutaneous | Evaluate
• Three Tigit players look to surprise in 2023
• The first big test for the son of Enhertu
• Big pharma’s new year catalysts
• Biotech’s key upcoming clinical results
• Catalysts ahead for the smaller players

Recent big data readouts

• Tecentriq surprises in adjuvant liver cancer
• Moderna looks to spoil GSK and Pfizer’s respiratory disease party
• Valrox shows signs of plateauing
• Arrowhead misses the target in alpha-1 antitrypsin deficiency
• Roivant shows Prometheus win was no fluke
• No Blys for Vera